{
  "schemaVersion": 1,
  "organisationId": "O-64659abfdb9a40c494756659e142e005",
  "slug": "beigene",
  "name": "BeiGene, Ltd.",
  "updatedAt": "2026-09-28T11:49:28.448035Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "BeiGene, Ltd., now named BeOne Medicines Ltd., is a global biopharmaceutical company focused on cancer. It discovers, develops, manufactures and commercializes oncology medicines, with the aim of making innovative treatments more accessible to patients worldwide. Its principal products include BRUKINSA (zanubrutinib), a treatment for certain blood cancers, and TEVIMBRA (tislelizumab), a cancer immunotherapy. [P71079343][P82528603][P95951577]\n\nFounded in 2010, the company has commercial operations in the United States, Europe and China, with a presence in other international markets. It reported approximately $5.3 billion in revenue for 2025 and employed nearly 12,000 people worldwide. BeiGene adopted the BeOne Medicines name in 2025 as part of its redomiciliation to Switzerland. [https://beonemedicines.com/about/history/][P113994149][P36827942][https://ir.beonemedicines.com/news/beone-medicines-launches-following-redomiciliation-to-switzerland-marking-a-new-chapter-in-global-oncology/3bf1505f-9411-4a38-b445-54544ad4c88e]\n[P71079343][P82528603][P95951577][P113994149][P36827942][https://beonemedicines.com/about/history/][https://ir.beonemedicines.com/news/beone-medicines-launches-following-redomiciliation-to-switzerland-marking-a-new-chapter-in-global-oncology/3bf1505f-9411-4a38-b445-54544ad4c88e]",
      "updatedAt": "2026-09-28T11:49:28.448035Z"
    },
    {
      "type": "PRODUCTS",
      "text": "BeiGene’s principal medicines are BRUKINSA (zanubrutinib), TEVIMBRA (tislelizumab) and PARTRUVIX (pamiparib). BRUKINSA is an oral Bruton’s tyrosine kinase (BTK) inhibitor designed for sustained target inhibition; its approved uses include several B-cell cancers, such as chronic lymphocytic leukemia, mantle cell lymphoma and Waldenström macroglobulinemia. [P31110943][P97059123] TEVIMBRA is a humanized anti-PD-1 antibody designed to minimize binding to Fcγ receptors and is used for selected solid tumors, including esophageal and gastric cancers, with indications varying by market. [P9430346][P45990522] PARTRUVIX is a PARP inhibitor approved in China for certain previously treated ovarian, fallopian-tube and primary peritoneal cancers. [T8819932][https://ir.beonemedicines.com/news/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated-advanced-ovarian-cancer/305b6eb6-ecb3-426a-b382-4bda796d8c1f]\n\nBeiGene also commercializes licensed cancer treatments in China. These include Amgen’s XGEVA, an anti-RANK ligand antibody; BLINCYTO, a bispecific T-cell engager targeting CD19 and CD3; and KYPROLIS, a proteasome inhibitor. Its licensed portfolio also includes REVLIMID and VIDAZA from Bristol Myers Squibb. [T8819932][P30760640][P34177038] Beyond marketed medicines, BeiGene participates in global clinical development of oncology drugs through its Amgen collaboration; it does not report a separate standalone services business. [P45768788]\n\nIn 2024, BRUKINSA generated approximately $2.64 billion, or 70% of BeiGene’s $3.78 billion in net product revenue. Tislelizumab generated approximately $621 million, or 16%; PARTRUVIX was not reported separately. [T11909341]\n[P31110943][P97059123][P9430346][P45990522][T8819932][T8819932][T8819932][T8819932][P30760640][P34177038][P45768788][T11909341][T11909341][T11909341][https://ir.beonemedicines.com/news/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated-advanced-ovarian-cancer/305b6eb6-ecb3-426a-b382-4bda796d8c1f]",
      "updatedAt": "2026-09-28T11:49:28.448035Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "BeiGene, Ltd., now operating as BeOne Medicines, has a registered seat in Basel, Switzerland, and facilities across the United States, China and Europe. Its principal sites include offices and laboratories in Beijing, a biologics manufacturing facility in Guangzhou, and a manufacturing and clinical research and development site in Hopewell, New Jersey. It also has a manufacturing facility in Suzhou and offices in cities including Shanghai and Basel. Its broader network extends to the Middle East and North Africa, South Africa and South America. [P107924883][P94272704]\n\nIn 2025, the United States accounted for approximately $2.88 billion, or 53.9%, of total revenue; China for $1.68 billion, or 31.4%; Europe for $611 million, or 11.4%; and the rest of the world for $172 million, or 3.2%. Revenue from products is attributed to the customer’s location, while other revenue is attributed to the jurisdiction where the related income is expected to arise. [T11028927][P10303432]\n[P107924883][P94272704][T11028927][T11028927][T11028927][T11028927][T11028927][P10303432]",
      "updatedAt": "2026-09-28T11:49:28.448035Z"
    },
    {
      "type": "SEGMENTS",
      "text": "BeiGene, Ltd. (now BeOne Medicines) reports one operating segment, **pharmaceutical products**. Its chief executive officer assesses performance and allocates resources on a consolidated basis, so the company does not report separate operating segments for individual medicines or regions. The segment encompasses its pharmaceutical product business; product sales accounted for approximately 99% of 2025 revenue, with other revenue accounting for approximately 1%. [P108273448][T11028927]\n\nWithin that single segment, BRUKINSA, a cancer medicine, contributed approximately 74% of 2025 product revenue, and TEVIMBRA approximately 14%; other products made up the remaining 12%. [T10514401] The company also discloses revenue by customer location rather than as geographic segments: the U.S. accounted for approximately 54% of 2025 total revenue, China 31%, Europe 11%, and the rest of the world 3%. [P10303432][T11028927]\n[P108273448][T11028927][T10514401][P10303432][https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index-headers.html]",
      "updatedAt": "2026-09-28T11:49:28.448035Z"
    },
    {
      "type": "HISTORY",
      "text": "BeiGene was founded in 2010 by John V. Oyler and Xiaodong Wang and initially focused on developing cancer medicines.[P188344804][P188116254] It completed a Nasdaq initial public offering in 2016, entered a licensing and supply agreement with Celgene for cancer medicines in China in 2017, and listed its shares in Hong Kong in 2018.[P188344804][P185818181][P17064496]\n\nIn 2019, BeiGene received its first approval for an internally developed medicine when the U.S. approved BRUKINSA (zanubrutinib) for certain patients with mantle cell lymphoma. China also approved its internally developed medicine tislelizumab that year.[P81819870][P181035402] BeiGene signed a broad development and commercialization collaboration with Amgen in 2019, then listed shares on Shanghai’s STAR Market in 2021.[P30760640][P17064496] In 2025, it changed its name to BeOne Medicines as part of a move of its corporate domicile to Switzerland.[https://ir.beonemedicines.com/news/beone-medicines-launches-following-redomiciliation-to-switzerland-marking-a-new-chapter-in-global-oncology/3bf1505f-9411-4a38-b445-54544ad4c88e]\n[P188344804][P188116254][P185818181][P17064496][P81819870][P181035402][P30760640][https://ir.beonemedicines.com/news/beone-medicines-launches-following-redomiciliation-to-switzerland-marking-a-new-chapter-in-global-oncology/3bf1505f-9411-4a38-b445-54544ad4c88e]",
      "updatedAt": "2026-09-28T11:49:28.448035Z"
    }
  ],
  "sources": [
    {
      "id": "P71079343",
      "href": "https://app.finbar.com/go?id=P71079343",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "P82528603",
      "href": "https://app.finbar.com/go?id=P82528603",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "P95951577",
      "href": "https://app.finbar.com/go?id=P95951577",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "https://beonemedicines.com/about/history/",
      "href": "https://beonemedicines.com/about/history/",
      "label": "beonemedicines.com"
    },
    {
      "id": "P113994149",
      "href": "https://app.finbar.com/go?id=P113994149",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "P36827942",
      "href": "https://app.finbar.com/go?id=P36827942",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "https://ir.beonemedicines.com/news/beone-medicines-launches-following-redomiciliation-to-switzerland-marking-a-new-chapter-in-global-oncology/3bf1505f-9411-4a38-b445-54544ad4c88e",
      "href": "https://ir.beonemedicines.com/news/beone-medicines-launches-following-redomiciliation-to-switzerland-marking-a-new-chapter-in-global-oncology/3bf1505f-9411-4a38-b445-54544ad4c88e",
      "label": "ir.beonemedicines.com"
    },
    {
      "id": "P31110943",
      "href": "https://app.finbar.com/go?id=P31110943",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "P97059123",
      "href": "https://app.finbar.com/go?id=P97059123",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "P9430346",
      "href": "https://app.finbar.com/go?id=P9430346",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "P45990522",
      "href": "https://app.finbar.com/go?id=P45990522",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "T8819932",
      "href": "https://app.finbar.com/go?id=T8819932",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "https://ir.beonemedicines.com/news/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated-advanced-ovarian-cancer/305b6eb6-ecb3-426a-b382-4bda796d8c1f",
      "href": "https://ir.beonemedicines.com/news/china-nmpa-approves-parp-inhibitor-pamiparib-for-patients-with-previously-treated-advanced-ovarian-cancer/305b6eb6-ecb3-426a-b382-4bda796d8c1f",
      "label": "ir.beonemedicines.com"
    },
    {
      "id": "P30760640",
      "href": "https://app.finbar.com/go?id=P30760640",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "P34177038",
      "href": "https://app.finbar.com/go?id=P34177038",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "P45768788",
      "href": "https://app.finbar.com/go?id=P45768788",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "T11909341",
      "href": "https://app.finbar.com/go?id=T11909341",
      "label": "BeiGene, Ltd. — Full financial report (2024 Y)",
      "documentId": "D-b64b159749ac4c00a91a2c5fda723e1c"
    },
    {
      "id": "P107924883",
      "href": "https://app.finbar.com/go?id=P107924883",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "P94272704",
      "href": "https://app.finbar.com/go?id=P94272704",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "T11028927",
      "href": "https://app.finbar.com/go?id=T11028927",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "P10303432",
      "href": "https://app.finbar.com/go?id=P10303432",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "P108273448",
      "href": "https://app.finbar.com/go?id=P108273448",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "T10514401",
      "href": "https://app.finbar.com/go?id=T10514401",
      "label": "BeiGene, Ltd. — Full financial report (2025 Y)",
      "documentId": "D-b2216cee5c9f435ab678b2bcbb20c697"
    },
    {
      "id": "https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index-headers.html",
      "href": "https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/0001628280-26-011946-index-headers.html",
      "label": "www.sec.gov"
    },
    {
      "id": "P188344804",
      "href": "https://app.finbar.com/go?id=P188344804",
      "label": "BeiGene, Ltd. — Full financial report (2016 Q 2)",
      "documentId": "D-74b8c54245514cff9e2ddaa68da6fa56"
    },
    {
      "id": "P188116254",
      "href": "https://app.finbar.com/go?id=P188116254",
      "label": "BeiGene, Ltd. — Full financial report (2016 Y)",
      "documentId": "D-5d7544f7ae54404e9309eaf61211de93"
    },
    {
      "id": "P185818181",
      "href": "https://app.finbar.com/go?id=P185818181",
      "label": "BeiGene, Ltd. — Full financial report (2017 Y)",
      "documentId": "D-921cc9efd1bd4537ab0eebccb17856c7"
    },
    {
      "id": "P17064496",
      "href": "https://app.finbar.com/go?id=P17064496",
      "label": "BeiGene, Ltd. — Full financial report (2023 Y)",
      "documentId": "D-7a2c1e793ddd4510ada7fcbd66b30ec8"
    },
    {
      "id": "P81819870",
      "href": "https://app.finbar.com/go?id=P81819870",
      "label": "BeiGene, Ltd. — Full financial report (2021 Y)",
      "documentId": "D-9f825c33499b438c8a523c871487a632"
    },
    {
      "id": "P181035402",
      "href": "https://app.finbar.com/go?id=P181035402",
      "label": "BeiGene, Ltd. — Full financial report (2019 Y)",
      "documentId": "D-ff0f02263ce8466ba2efaa6a6f4738d2"
    }
  ]
}